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Managing the implementation of new technology in a pharmaceu-
tical development environment has provided challenges and oppor-
tunities to obtain bene￿ts from technologies, e.g. laboratory
automation. Successful application of new techniques requires a
dedicated resource. Within Pharmaceutical Technologies, this was
initially a single person, who has since evolved into a team
dedicated to the investigation and development of robotics and
non-invasive analytical techniques. Pharmaceutical development is
an important interface between research and commercial manu-
facturing. In research, the success of genomics and combinatorial
chemistry will result in a signi￿cant increase in the number of
development compounds, and this, combined with the desire of
commercial manufacturing to move towards parametric release,
puts an emphasis on the need for rapid analytical methods. Some
ideas on the techniques that will be required to meet these goals
will be described together with their impact on automation.
Introduction
In research, platform technologies including DNA se-
quencing, combinatorial chemistry and high-throughput
screening (HTS) have increased the productivity in
compound and lead generation. HTS can now provide
the capability of screening 100000 compounds per week;
this will soon increase to 100000 compounds per day.
Combinatorial chemistry israpidly developing to provide
the libraries of compounds to keep up with the screening
capacity and to increase the quality of development
candidates. This capability has resulted in SB working
on some 200 drug targets in 1997, which is nearly half of
the 500 targets available to the entire pharmaceutical
industry up until 1995. The supply of compounds into
pre-clinical development will therefore see a signi® cant
increase in the future. The e￿ ect of this potential increase
in development compounds on the pre-clinical organ-
ization in terms of the development of automation and
other new technologies will be discussed with particular
emphasis on managing its implementation in pharma-
ceutical development.
Discussion
Development of new technologies in pre-clinical development
The departments in pre-clinical development are intro-
ducing technologies to improve their e￿ ciency. In chemi-
cal development, automation is being employed to help
optimize the reaction steps during scale-up using equip-
ment developed in Europe by Anachem Ltd. This
equipment comprises a multiple-reaction block (STEM
corporation), Gilson 233XL autosampler and an HPLC
system. Spectroscopic methods including infrared are also
being employed to monitor reactions on-line in process
chemistry providing more rapid feedback on the progress
of the reactions compared to traditional separation
methods. Chromatography for drug substance purity
determination and puri® cation is being performed using
parallel HPLC columns. The equipment supplied by
Biotage isa typical example of this concept. Fast-gradient
HPLC using short columns (2mm ID£10mm in length)
is also being applied to reaction monitoring enabling run
times to be reduced to ¹1min.
In the analysis of bio¯ uids, the implementation of LC/
MS technology has increased productivity markedly with
analysis times typically less than 5min. The chromato-
graphy in this case is used more as a means of sample
introduction, and the `separation’ is performed by the
mass spectrometer. The requirement for high-speed
sample introduction for LC/MS technology has resulted
in the development of faster autosamplers for serial
sample introduction. More recently, multi-line auto-
samplers have been developed to increase sample
throughput into mass spectrometers.
The techniques described above are by no means an
exhaustive account of the analytical technologies being
developed to increase the e￿ ciency of some areas in pre-
clinical development; however, this does provide an over-
view of some of the trends in future technologies. The
main themes that are evident include: automation; rapid
separations; parallel analytical processing; fast sensitive
and selective detectors; and non-invasive analysis.
These developments will improve the rate of compound
supply, which in turn will impact the clinical supplies
operation. In drug product analysis, well-established
automation systems for tablet processing and dissolution
of solid oral dosage forms have been implemented. These
technologies, however, will not be su￿ cient to keep up
with the increase in development candidates from re-
search or with the emerging alternative technologies that
will compete with the current analytical methods.
Managing the implementation of new analytical techniques in
Pharmaceutical Technologies ( UK)
Pharmaceutical Technologies is responsible for the for-
mulation and analytical development, clinical trials
supply and technology transfer of new products to manu-
facturing facilities. Within Pharmaceutical Technologies
(UK), the e￿ ort devoted to developing and implement-
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has gradually increased over the past 6years. Initially a
single person was assigned to developing and validating
new automated methods using the Zymate
TM dissolution
robot and the Benchmate
TM within Analytical Develop-
ment. In 1992, the department was reorganized into a
multidisciplinary team-based structure. This resulted in
the traditional analytical and formulation departments
being reorganized into `product’ teams comprising for-
mulators and analysts together with several specialist
`support’ teams that perform tasks, e.g. microbiology
and automated methods (Analytical Support). A central
team to develop and validate was considered to be most
e￿ ective for several reasons. (i) The experience gained
from performing this process could be built up in the
Analytical Support team and then shared with the Prod-
uct teams on a timely basis enabling faster implementa-
tion of automated methods. (ii) Quali® cation and change
control of robotic systems is easier to perform using a
central team. (iii) Consistent approaches to validation of
automated methods are more likely when the same
scientists are involved in the process.
The reorganization of the department into this team-
based structure also resulted in the Analytical Support
team facing a signi® cant change in the interfaces and
provided communication challenges. The team has
moved from being in a department in which all the
analytical work was concentrated to interfacing with
more than 10 individual teams with projects at various
stages of development and each progressing at di￿ erent
speeds. Although establishing the initial outline for each
project was time consuming, keeping the information
up to date is relatively easy. The information typically
recorded is shown below.
(1) Compound.
(2) Priority.
(3) Quali® cation batch manufacturing date.
(4) Status of automated method for:
TPWII
TM
Powder
Bulk assay
Content uniformity
Degradation pro® le
MultiDose
TMdissolution.
(5) Product team.
In 1997, Pharmaceutical Technologies (UK) was con-
solidated from three di￿ erent sites into a single building
at Harlow, UK. During the past 18months, the resource
and remit of this team involved with new analytical
technologies has now been widened to cover the follow-
ing.
(1) Implementation of automated methods (three scien-
tists).
(2) Development of non-invasive techniques, e.g. near-
infrared and ultrasound (two scientists).
(3) Investigation of in vitro `dissolution’ systems for
improving the prediction of in vivo performance of
poorly soluble drugs (one scientist).
To drive the development of new technology (e.g. non-
invasive analytical methods) forward faster in the UK,
collaborations have been set up with groups external to
SB. There are several reasons for these links. Firstly, to
increase the level of resource devoted to new technology
development without increasing the headcount. Sec-
ondly, to promote the development and regulatory ac-
ceptance of non-invasive technologies, e.g. near-infrared
and more recently ultrasound. An example of this
scenario is collaborations coordinated by the Pharma-
ceutical and Analytical Sciences Group (PASG) in the
UK (® gure 1). This group represents the major research-
based pharmaceutical companies in the UK with the
main aims of: (i) providing a uni® ed voice on analytical
issues via the Association of British Pharmaceutical In-
dustry to international regulatory agencies; (ii) enhan-
cing awareness of analytical science in education; and
(iii) promoting the image and profession of pharmaceu-
tical analysis. The PASG has sponsored the setting up of
the Near Infrared Centre of Excellence at the London
School of Pharmacy by supporting four PhD students.
The Centre has been working in four key areas in which
the regulators have concerns to aid the acceptance of the
technology. Collaboration has also just been initiated on
the application of ultrasound technology to pharmaceu-
tical analysis.
Development of new technologies in pharmaceutical analysis
Automation of the analysis of pharmaceutical drug prod-
ucts over the past 30years has resulted in relatively small
stepwise improvements in e￿ ciency. In the 1970s, auto-
mation of traditional colorimetric assays for drugs, e.g.
penicillins was achieved by the use of autoanalysers. This
was followed by the advent of HPLC, and in the early
1980s unattended analysis was implemented utilizing
autosamplers. Dissolution robots became available in
the mid-1980s followed by the tablet processing systems
Pharmaceutical and
Analytical Sciences Group
(PASG)
 Technology Sub-Group
- Company Reps
-  Instrument Companies
-  Innovation Group
-----------------------------------
- Academic Links Regulators
Figure 1. PASG technology development process.
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prove e￿ ciency in sample throughput but these are
unlikely to be su￿ cient to keep pace with the develop-
ments in research and the needs of commercial manu-
facturing.
The weaknesses of current pharmaceutical analytical
processes will be outlined to enable better understanding
of how appropriate newer technologieswill be used in our
laboratories in the future. A generic process for drug
product analysis is outlined in ® gure 2.
(1) Request for analysis. In the team-based organizations
operated by Pharmaceutical Technologies in which
analysts and formulators work closely together, a
traditional request for analysis form is not required
as the team inherently knows the status of its own
samples. However, a laboratory information man-
agement system (LIMS) is used to track information
on samples. This information is entered manually
together with the tests required for the sample.
Improvements needed include entry of sample in-
formation by bar code and speci® cation/test informa-
tion already available in the system enabling
automatic generation.
(2) Sampling. This is critical in any analysisprocess and is
generally performed manually, which can be time
consuming and laborious. The sample size taken for
the release testing of a drug product is generally very
small compared with the batch size, e.g. 100 tablets
from a 100000 tablet batch. Furthermore, 30 tablets
or less are typically used to provide the assay and
content uniformity data to release the batch. Tech-
niques that enable the analysis to be performed non-
destructively without sampling in the manufacturing
area either at-line or on-line are needed. This would
enable a much larger and more representative
sample size to be taken.
(3) Analysis. The release of a batch of drug product is
generally dependent on limited in-process data and
on testing of the ® nished product against a speci® ca-
tion. Several improvements to this process are re-
quired. Firstly, more information on the quality of
the product during the manufacturing process is
required, and as discussed above, rapid non-destruc-
tive on-line techniques are required. The ultimate
aim of this type of testing is to have su￿ cient in-
process controls to enable a product to be released
with little or no ® nal product testing, i.e. parametric
release. Secondly, the current time for automated
tablet preparation (e.g. 15min) is relatively long
compared with the time for required HPLC or UV
analysis, therefore more rapid sample preparation
systems are required. Non-destructive methods
would elegantly overcome this problem, but this will
not be possible for all products. For example, for low-
dose products, linking the separation with a sensitive
detector (e.g. LC/MS) would o￿ er a good solution.
Finally, automatic results transfer to LIMS is typi-
cally available for outputs from HPLC systems. Links
between robotic systems, e.g. the TPWII
TM and
MultiDose
TM and the LIMS are also needed to
provide easy transfer of sample information during
the analysis. In the future, facile results transfer of the
results from spectroscopic techniques, e.g. NIR and
mass spectroscopy will also be needed.
(4) Documentation. The documentation of practical work
from an analysis is time consuming and has resulted
in analysts spending more time out of the laboratory.
Typically, 15% of an analysts’ time can be spent
entering data into laboratory notebooks. In many
laboratories, LIMS are used in an attempt to reduce
the documentation burden, but the success and
savings in time are largely dependent on the environ-
ment in which the system is used. In development,
the rapidly changing project requirements tend to
make the use of LIMS problematic such that in-
formation is recorded in laboratory notebooks, and
the summary of results and associated references are
transferred to LIMS. The net result from this process
is that a proportion of information is duplicated as
hardcopy and electronic ® les. In a commercial
manufacturing QC, laboratories’ work tends to be
more predictable than in R&D, which has resulted in
LIMS being implemented more successfully. Inter-
facing instruments including balances, HPLCs, UV
spectrophotometers and associated robots to LIMS
are needed to reduce the time spent writing-up in
laboratory notebooks.
To reduce the wasted e￿ ort in transcribing in-
formation, electronic notebooks are being developed.
Request for analysis
Sampling
Analysis
· Sample preparation
· Measurement
· Data Analysis
Documentation
Review of data
Approval of data
Reporting of results
Figure 2. Generic process for drug product analysis.
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Association (CENSA) is one such group that is
moving the development of this technology forward
[1]. A key element in the implementation of electro-
nic information management is greater standardiza-
tion of the working practices in laboratories. The
increased use of robotics will help achieve this goal.
(5) Review of data. Reviewing of data is the backbone of
the GMP process. Automated checking by the
LIMS of key information in an analytical method
should be possible. For example, LIMS could alert
the analyst if the standard weights, sample weights,
system suitability and the associated results are not
within predetermined limits. This scenario is best
suited to a standardized process operated by auto-
mated systems.
(6) Approval of data. For a product manufactured by a
well-de® ned process, checking of results against a
typical release speci® cation can be undertaken auto-
matically by LIMS. This has been performed
successfully for many years in commercial manu-
facturing laboratories. Implementation in a develop-
ment environment has not been widespread, which is
probably due to the less well-de® ned processes and
procedures for manufacturing and analysing the
product.
(7) Reporting of results. In R&D, results are typically
required for a number of main purposes. Firstly, to
release product for clinical trials, which requires the
generation of a Certi® cate of Analysis. Secondly, the
generation of stability data to support product regis-
tration, which requires the data from several storage
conditions tabulated in a form suitable for direct
transfer into the regulatory document. The report
generation capabilities of the LIMS system must be
more ¯ exible to provide data in the required form.
Achieving this goal would dramatically decrease
the time spent compiling and checking regulatory
dossiers.
Technology needs of manufacturing
Rapid, reliable, easy-to-use and cost-e￿ ective methods
are required by quality control (QC) laboratories in
manufacturing. Methods based on robotics exhibit some
of these desired attributes. The QC departments typically
now require robotic methods for assay, content unifor-
mity and dissolution methods from R&D prior to the
manufacture of the quali® cation batches. In addition, for
the validation batches, automated methods samples are
needed for the analysis of powder samples taken at
various time points from the mixers to demonstrate the
homogeneity of the blending process. This work typically
generates hundreds of powder samples for assay using
TPWII
TM. More recently, QC laboratories are request-
ing NIR methods for assay, content uniformity and
powder blend analysis. NIR o￿ ers rapid and non-de-
structive analysis compared to automated UV and
HPLC technologies. This technique also has the added
advantage of generating little waste compared with
conventional techniques.
Analytical techniques for the next millennium
The discussion above indicates that there are emerging
trends in analytical technologies that will increase pro-
ductivity in pharmaceutical development, and these will
be outlined below.
(1) Parallel analytical processing. To provide traditional
analysis, e.g. HPLC at-line to monitor a manu-
facturing process, much faster systems are required.
This could be achieved using fast HPLC systems;
however, sample preparation instrumentation would
have to be re-engineered to keep up with the
separation speeds. The application of ultrasonic tech-
nology may help solve this problem. Parallel sample
preparation and separation systems that enable the
analysis to be completed in ¹1min will be required
to compete with near-infrared.
(2) Miniaturization. Computer `chip’ technology is being
developed to perform analyses. The so-called `micro-
TAS’ (total analysis system) concept [2] combines
sampling, separation, reaction and detection onto an
integrated platform. This device is typically fabri-
cated on silicon, glass or polymer wafers, on which
micro minute features that are typically between 1
and 50microns in size, are photoetched. The key
bene® ts of this technology to pharmaceutical analysis
are very rapid analysis time (seconds) and the small
size of the equipment. This technology would lend
itself to at-line analysis and to early development
work when little compound is available. Sample
preparation systems to match these devices are
required before these devices are commercialized.
The recent investment by Hewlett Packard in Cali-
per Technologies is an indication of the level of
interest in `chip’ technology for analysis.
(3) Non-invasive analysis. Near-infrared [3] spectroscopy
and Raman spectroscopy [4] are alternative tech-
niques for the analysis of pharmaceutical products.
No sample preparation is required, therefore analysis
is rapid and lends the technologies to in-process
testing as well as ® nal product analysis. These tech-
nologies in most instances rely on building libraries of
acceptable samples and comparing the unknown
against this library. Linking these techniques to
microscopes is now providing the capability of ima-
ging materials with resolution down to about 10±
20microns. This technology is being used for trou-
bleshooting; however, there may be utility for em-
ploying imaging in the routine testing of products
and providing early warning of stability problems.
Perkin Elmer have developed an automated system
NIR imaging instrument. For highly potent low-dose
drug products these techniques are generally not
sensitive enough, and more traditional separation
methods would be required for analysis.
(4) Sensor technology. Low levels of volatile residues in
materials, e.g. packaging components are increas-
ingly a￿ ecting the stability of drug products. Form-
aldehyde is a compound that has been shown to
cross-link gelatin capsules and to cause stability
problems with products. Neural nose technology
has been used to monitor volatile residues in
materials, particularly in the food industry. This
technology uses electrically conducting organic poly-
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together with neural networks to classify the aromas.
Monitoring of raw materials and products on stabi-
lity may be a rapid means of ® ngerprinting materials
and predicting problems with volatile residues.
(5) Fast sensitive and selective detectors. The rapid develop-
ment of LC/MS in terms of lower cost, ease of use and
quantitative performance has meant that these
systems will realize their potential to become routine
detectors for HPLC. This may enable fast `universal’
liquid chromatography methods to be used in which
the chromatography system is more of a means of
sample introduction and any incomplete separations
could be compensated by the mass spectrometer.
This technology should lead to reduced time for
method development and validation for quantitative
methods, and provide more sensitive detection for
degradation products, thus giving earlier warning of
stability problems.
(6) Informatics. The technologies described above in (1)±
(5) will provide more information on an increased
number of samples. Experience to date with LIMS
systems in a development environment indicates that
signi® cant improvements will be required to inte-
grate information collection from both instruments
and scientists (electronic laboratory notebooks).
Once the information resides in the information
management system, better reporting packages and
links to regulatory management documents are
necessary.
Summary
The increased ¯ ow of development compounds from
research and the needs of commercial manufacturing will
require new technologies to be implemented. The trends
in analytical techniques to meet these needs include:
parallel analytical processing; miniaturization; non-inva-
sive technologies; sensors; fast sensitive and selective
detectors together with associated information manage-
ment systems. New technologies are providing challenges
and opportunities in pharmaceutical development. Suc-
cessful application of automated methods and new
analytical techniques requires a central team dedicated
to the investigation and development of automated
methods and non-invasive analytical techniques. Colla-
borations with other pharmaceutical companies and
academic centres are providing more resources to intro-
duce the technologies in a highly regulated pharmaceu-
tical environment.
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